Scientists at NYU Langone Health have developed an experimental drug that may reduce serious complications caused by Diabetes.
The drug, named RAGE406R, was tested on mice. It was found to reduce inflammation, limit cellular damage, and improve recovery in key organs such as the heart and kidneys. Researchers also observed faster wound healing, which is a major challenge for people with Diabetes.
Unlike traditional Diabetes treatments, RAGE406R does not lower blood sugar. Instead, it targets cellular damage by blocking the interaction between two harmful proteins, RAGE and DIAPH1. These proteins play a key role in tissue injury and inflammation.
The drug focuses on advanced glycation end products (AGEs), which form when sugar binds with proteins or fats in the body. In patients with Diabetes, AGEs build up faster, causing inflammation and organ damage. By preventing AGEs from interacting with RAGE and DIAPH1, the drug helps protect cells and tissues from harm.
Researchers applied RAGE406R directly to the skin of diabetic mice. The results showed faster wound healing, suggesting that the drug could help treat slow-healing wounds in diabetic patients. Wound care is a critical concern for people living with Diabetes, as delayed healing can lead to severe infections.
The study highlights a new approach to managing Diabetes complications. By targeting the underlying cellular damage rather than blood sugar levels, RAGE406R could complement existing treatments and improve patient outcomes.
In other related news also read Study Reveals Plastic Bottles May Raise Type 2 Diabetes Risk
Further research is needed to confirm the drug’s safety and effectiveness in humans. However, the findings provide hope for a treatment that addresses organ damage, inflammation, and chronic wounds in Diabetes patients.
